Prostate Cancer

Gene alteration may render some prostate cancers less responsive to radiation therapy

Published in Cancer Weekly, August 20th, 2002

Identifying the status of the p53 gene product in certain prostate cancer patients could help in determining the best treatment, according to a new study published in the July 2002 issue of the International Journal of Radiation Oncology, Biology and Physics.

Researchers set out to explore the cause of treatment failures following radiation therapy in some prostate cancer patients. Focusing in on the p53 gene, they hypothesized that the active or inactive state of the gene product may play a role in whether the cancer is successfully treated by radiation.

When normal, the p53 gene product has been shown to be a tumor killer whose natural...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-08-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry